Contrasting Ocera Therapeutics (TZYM) & ChemoCentryx (CCXI)

Ocera Therapeutics (NASDAQ: TZYM) and ChemoCentryx (NASDAQ:CCXI) are both small-cap biopharmaceuticals companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Ocera Therapeutics and ChemoCentryx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocera Therapeutics N/A -215.86% -101.91%
ChemoCentryx N/A -67.57% -20.43%

Volatility and Risk

Ocera Therapeutics has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ocera Therapeutics and ChemoCentryx’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Ocera Therapeutics N/A N/A N/A ($1.05) -1.63
ChemoCentryx $11.94 million 30.59 -$39.96 million ($0.60) -12.48

Ocera Therapeutics has higher revenue, but lower earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Ocera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Ocera Therapeutics and ChemoCentryx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocera Therapeutics 0 0 0 0 N/A
ChemoCentryx 0 1 1 0 2.50

Institutional & Insider Ownership

49.2% of ChemoCentryx shares are held by institutional investors. 26.2% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ChemoCentryx beats Ocera Therapeutics on 7 of the 8 factors compared between the two stocks.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

ChemoCentryx Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Receive News & Ratings for Ocera Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply